LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

Home・Aandelen Lijst・Design Therapeutics Inc

Design Therapeutics Inc

Open

11.92 -16.99

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.8

Max

16.73

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.6M -18M
EPS	-0.29
Werknemers	54
EBITDA	-1.5M -20M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+18.3% upside

Dividenden
By Dow Jones
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	175M 975M
Vorige openingsprijs	28.91
Vorige sluitingsprijs	11.92

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

3.26 / 3.63 Steun & Weerstand

Design Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 mei 2026, 23:53 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mei 2026, 22:47 UTC

Populaire aandelen

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mei 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mei 2026, 22:00 UTC

Belangrijke Marktbewegers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mei 2026, 18:09 UTC

Belangrijke Marktbewegers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mei 2026, 23:50 UTC

Marktinformatie

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mei 2026, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

17 mei 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mei 2026, 23:36 UTC

Marktinformatie

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mei 2026, 23:07 UTC

Acquisities, Fusies, Overnames

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mei 2026, 23:06 UTC

Acquisities, Fusies, Overnames

UOB: Share Sale Agreements Entered With Singland Properties

17 mei 2026, 23:05 UTC

Acquisities, Fusies, Overnames

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Acquire Stake for $389 Million

17 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mei 2026, 16:27 UTC

Acquisities, Fusies, Overnames

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mei 2026, 15:26 UTC

Acquisities, Fusies, Overnames

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mei 2026, 08:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:59 UTC

Acquisities, Fusies, Overnames

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mei 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mei 2026, 21:16 UTC

Marktinformatie

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 20:19 UTC

Populaire aandelen

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mei 2026, 19:41 UTC

Acquisities, Fusies, Overnames

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mei 2026, 19:35 UTC

Marktinformatie

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mei 2026, 18:35 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Peer Vergelijking

Prijswijziging

Design Therapeutics Inc Prognose

Koersdoel

By TipRanks

18.3% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 17 USD 18.3%

Hoogste 21 USD

Laagste 14 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Design Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Design Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.26 / 3.63Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.